Author/Authors :
Kamalinejad, Mohammad Department of Pharmacognosy - School of Pharmacy - Shaheed Beheshti University of Medical Sciences, Tehran, Iran - Research and Development Department - Behdaneh Baran Salem Abi Company, Tehran, Iran , Sarmadian, Hossein Department of Infectious Diseases - Faculty of Medicine - Arak University of Medical Sciences, Arak, Iran , Shokouhi, Farzaneh Department of Infectious Diseases - Faculty of Medicine - Arak University of Medical Sciences, Arak, Iran , Dadmehr, Majid Department of Traditional Medicine - School of Persian Medicine - Iran University of Medical Sciences, Tehran, Iran , Bahrami, Mohsen Researcher in Persian Medicine, Tehran, Iran , Dehnad, Afsaneh Department of Medical Education - School of Health Management and Information Sciences - Iran University of Medical Sciences, Tehran, Iran , Almasi-Hashiani, Amir Department of Epidemiology - School of Health - Arak University of Medical Sciences, Arak, Iran , Solgi, Mohammad Saleh Traditional and Complementary Medicine Research Center - Arak University of Medical Sciences, Arak, Iran , Salehi, Mehdi Traditional and Complementary Medicine Research Center - Arak University of Medical Sciences, Arak, Iran , Kamalinejad, Fatemeh School of Biomedical Sciences - University of Western Australia, Australia - Research and Development Department - Behdaneh Baran Salem Abi Company, Tehran, Iran , Latifi, Amirhossein Traditional and Complementary Medicine Research Center - Arak University of Medical Sciences, Arak, Iran
Abstract :
Since the outbreak of the COVID-19 pandemic, we have witnessed extensive morbidity and mortality worldwide. However, an appropriate pharmaceutical treatment has not yet been introduced for this disease, and finding a safe and effective treatment is still ongoing. This study aimed to evaluate the safety and efficacy of Tiban (Mocozift) syrup (an herbal product of Trachyspermum ammi (L.) Sprague (Ajwain) and Ziziphus jujuba Mill. (jujube)) in adult patients with COVID-19. Patients with laboratory-confirmed SARS-CoV-2 infection were enrolled and randomly assigned to receive either placebo or Tiban syrup 5 cc, three times a day for 14 days, in addition to standard medications of COVID-19. Improvement in clinical outcomes, including cough, fatigue, dyspnea, appetite, and the occurrence of in-hospital mortality, were recorded.A total of 50 patients completed the study. The mean age of the patients was 56.5 years. There were 21 (42%) male and 29 (58%) female patients. There was a significant reduction in dyspnea after taking medication (p=0.001). Patients’ appetite significantly increased in the Tiban group (p=0.001). Also, a significant decrease was observed in the severity of fatigue score in the Tiban group (p=0.001). Compared to the placebo group, an increase in appetite and a decrease in fatigue occurred earlier in the Tiban group.The findings of this study suggest that the combination therapy with Tiban syrup and conventional medicine can reduce severity of dyspnea and fatigue, while it can increase appetite in patients with mild to moderate COVID-19.
Keywords :
Appetite , COVID-19 , Dyspnea , Fatigue , Mocozift , Tiban , Trachyspermum ammi , Ziziphus jujube
